GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • S. Karger AG  (2)
  • Gok Oguz, Ebru  (2)
  • 1
    Online Resource
    Online Resource
    Characteristics and Survival Results of Peritoneal Dialysis Patients Suffering from COVID-19 in Turkey: A Multicenter National Study
    S. Karger AG ; 2022
    In:  Kidney and Blood Pressure Research Vol. 47, No. 10 ( 2022), p. 605-615
    Details
    In: Kidney and Blood Pressure Research, S. Karger AG, Vol. 47, No. 10 ( 2022), p. 605-615
    Abstract: 〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 We aimed to study the characteristics of peritoneal dialysis (PD) patients with coronavirus disease-19 (COVID-19), determine the short-term mortality and other medical complications, and delineate the factors associated with COVID-19 outcome. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 In this multicenter national study, we included PD patients with confirmed COVID-19 from 27 centers. The baseline demographic, clinical, laboratory, and radiological data and outcomes at the end of the first month were recorded. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 We enrolled 142 COVID-19 patients (median age: 52 years). 58.2% of patients had mild disease at diagnosis. Lung involvement was detected in 60.8% of patients. Eighty-three (58.4%) patients were hospitalized, 31 (21.8%) patients were admitted to intensive care unit and 24 needed mechanical ventilation. Fifteen (10.5%) patients were switched to hemodialysis and hemodiafiltration was performed for four (2.8%) patients. Persisting pulmonary symptoms ( 〈 i 〉 n 〈 /i 〉 = 27), lower respiratory system infection ( 〈 i 〉 n 〈 /i 〉 = 12), rehospitalization for any reason ( 〈 i 〉 n 〈 /i 〉 = 24), malnutrition ( 〈 i 〉 n 〈 /i 〉 = 6), hypervolemia ( 〈 i 〉 n 〈 /i 〉 = 13), peritonitis ( 〈 i 〉 n 〈 /i 〉 = 7), ultrafiltration failure ( 〈 i 〉 n 〈 /i 〉 = 7), and in PD modality change ( 〈 i 〉 n 〈 /i 〉 = 8) were reported in survivors. Twenty-six patients (18.31%) died in the first month of diagnosis. The non-survivor group was older, comorbidities were more prevalent. Fever, dyspnea, cough, serious-vital disease at presentation, bilateral pulmonary involvement, and pleural effusion were more frequent among non-survivors. Age (OR: 1.102; 95% CI: 1.032–1.117; 〈 i 〉 p 〈 /i 〉 : 0.004), moderate-severe clinical disease at presentation (OR: 26.825; 95% CI: 4.578–157.172; 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001), and baseline CRP (OR: 1.008; 95% CI; 1,000–1.016; 〈 i 〉 p 〈 /i 〉 : 0.040) were associated with first-month mortality in multivariate analysis. 〈 b 〉 〈 i 〉 Discussion/Conclusions: 〈 /i 〉 〈 /b 〉 Early mortality rate and medical complications are quite high in PD patients with COVID-19. Age, clinical severity of COVID-19, and baseline CRP level are the independent parameters associated with mortality.
    Type of Medium: Online Resource
    ISSN: 1420-4096 , 1423-0143
    URL: Article
    DOI: 10.1159/000526909
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2022
    detail.hit.zdb_id: 1482922-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey
    S. Karger AG ; 2023
    In:  Nephron Vol. 147, No. 5 ( 2023), p. 272-280
    Details
    In: Nephron, S. Karger AG, Vol. 147, No. 5 ( 2023), p. 272-280
    Abstract: 〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 There are not enough data on the post-CO­VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88–6.0] years and 3.0 [2.0–5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40–57] years and 56 [IQR: 46–64] years, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia.
    Type of Medium: Online Resource
    ISSN: 1660-8151 , 2235-3186
    URL: Article
    DOI: 10.1159/000526234
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2023
    detail.hit.zdb_id: 2810853-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...